Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of arachidonic acid, is a naturally occurring prostaglandin with potent vasodilatory activity and inhibitory activity of platelet aggregation.
VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
Published Studies Related to Veletri (Epoprostenol)
Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and
to prevent restenosis after coronary angioplasty: results of a randomised placebo
controlled trial. 
PATIENTS: 135 patients with successful coronary angioplasty... CONCLUSION: The dose of PGI2 given was designed to limit side effects and as a
How has epoprostenol changed the outcome for patients with pulmonary arterial
AIMS: Pulmonary arterial hypertension (PAH), characterized by increased pulmonary
vascular resistance and pulmonary artery pressure, is a significant cause of
morbidity and mortality in children and adults. Prior to 1995, there were no
approved therapies for PAH...
Longterm survival among patients with scleroderma-associated pulmonary arterial
hypertension treated with intravenous epoprostenol. 
12-week study... CONCLUSION: This study reports longterm survival rates for patients with
Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary
arterial hypertension: a controlled trial. 
IV epoprostenol... CONCLUSIONS: SC treprostinil is effective in pulmonary arterial hypertension and
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary
Intravenous epoprostenol is currently FDA approved for management of primary
pulmonary hypertension, but it requires intravenous infusion and is associated
with adverse effects. The objective of this study was to evaluate the effects of
an epoprostenol analog, treprostinil, for management of pulmonary hypertension...
Clinical Trials Related to Veletri (Epoprostenol)
Prostacyclin's Effect on Platelet Responsiveness [Completed]
Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage [Completed]
The purpose of this study is to determine whether prostacyclin is effective in prevention of
cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) [Completed]
The purpose of this multicentre, open label, single-arm study in approximately 20 adult
patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of
epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH).
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement [Recruiting]
Research study evaluating the individual and combined effects of inhaled medications, nitric
oxide and prostacyclin, on the function of the right heart after surgery for either heart
transplant or for left ventricular assist device (LVAD) placement. The investigators hope to
learn if these two medications, when given together after surgery, improve right heart
function by lowering blood vessel pressures in the lungs. The investigators hope to learn if
the combined effects of these two medications are better than either medication used alone.
Participants were selected as a possible participant in this study because right heart
problems are common during and after surgery for heart transplant and for LVAD placement. In
addition, the inhaled medication, nitric oxide, is always given during and after these two
types of surgeries at Stanford to help improve how the right heart functions.
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery [Terminated]
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability
(problems related to unstable blood pressure) during and after open heart surgery.
Tezosentan is an investigational intravenous drug that blocks the endothelin receptors.
This clinical trial will assess the potential benefit of tezosentan compared with placebo in
the treatment of patients undergoing open heart surgery with cardiopulmonary bypass (CPB).
Treatment time is from the start of surgery up to 24 hours.